Cardiome Pharma (CRME) drops on deal with SteadyMed

Cardiome Pharma Corp.

shares faded 2.5% to $9.15, as the company and SteadyMed Ltd. announced an exclusive license and supply agreement for Cardiome to commercialize Trevyent® in certain regions outside the U.S. if Trevyent is approved for the treatment of pulmonary arterial hypertension, or PAH, in such regions. Share volume was 82,900